Abstract
Objective
The aim of this work was to evaluate anti-tumor effects of mDRA-6 plus nimesulide on a human hepatocellular cancer cell line, SMMC-7721, and study the main mechanisms.
Methods
The DR5 receptor of SMMC-7721 cells was detected by flow cytometry (FCM). For further experimental application, SMMC-7721 cells were treated with proper dose of mDRA-6, nimesulide, or mDRA-6 plus 200 μmol/L nimesulide; untreated SMMC-7721 cells were comparably set as control. Cytotoxicity was tested by MTT assay; cell morphology was examined using Hoechst 33258 staining; and apoptosis was determined by FCM.
Results
The positive rate of DR5 on SMMC-7721 was 95.0%. Either mDRA-6 or nimesulide alone induces SMMC-7721 cell death in a dose-dependent manner. Treatment of 1,600 ng/mL mDRA-6 for 12h led to a cell-death rate of 35.0%, while an increased cell-death rate (91.1%) was found under the same condition of mDRA-6 treatment supplemented with 200 μmol/L nimesulide. Hoechst 33258 and Annexin V/PI staining confirmed apoptosis as the main cause of this anti-tumor response.
Conclusion
Both mDRA-6 and nimesulide can induce apoptosis of SMMC-7721 cells, and they have synergistic anti-tumor activities against SMMC-7721.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 1995, 3: 673–682.
Ichikawa K, Liu W, Zhao L et al. Tumoricidal activity of a novel antihuman DR5 monoclonal antibody without hepatocyte cytotoxicity. Nature Medicine, 2001, 7: 954–960.
Takeda K, Yamaguchi N, Akiba H, et al. Induction of Tumor-specific T Cell Immunity by Anti-DR5 Antibody Therapy. J Exper Med, 2004, 199: 437–448.
LeBlanc HN and Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ, 2003, 10: 66–75.
Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and death domain-containing receptor for TRAIL. Science, 1997, 277: 815–818.
Pitti RM, Marsters SA, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem, 1996, 271: 12687–12690.
Mongkolsapaya J, Grimes JM, Chen N, et al. Structure of the TRAILDR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat Struct Biol, 1999, 6: 1048–1053.
Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptos-inducing ligand in vivo. Nat Med, 1999, 5: 157–163.
Howe LR, Dannenberg AJ. A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer. Semin Oncol, 2002, 29: 111–119.
Li XH, Li JJ, ZhanG HW, et al. Nimesulide inhibits tumor growth in mice implanted hepatoma:overexpression of Bax over Bcl-2. Acta Pharmacol Sin, 2003, 24: 1045–1050.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by a grant from the National Nature Sciences Foundation of China (No. 30571697).
Rights and permissions
About this article
Cite this article
Zhang, J., Liu, Y., Ma, Z. et al. Combined anti-tumor effects of mDRA-6 and nimesulide on human hepatocellular cancer cell line SMMC-7721. Chin. -Ger. J. Clin. Oncol. 7, 694–697 (2008). https://doi.org/10.1007/s10330-008-0130-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10330-008-0130-z